We often chase after the hottest AI or tech trends here in the forum. But the real returns often lie where it seems "boring" at first glance - with the real hidden champions.
Today I would like to introduce you to a Scandinavian company that can be found in almost every major modern hospital in the world, enjoys an absolute monopoly position, operates with extremely high margins and - here's the kicker - has just been massively punished on the stock market. A classic, fundamental turnaround candidate: CellaVision AB. $CEVI (-2,11%)
1. what the company does
CellaVision has revolutionized traditional blood analysis. Where a lab technician used to sit bent over a microscope for hours, manually counting blood cells, the Swedes now use digital systems. The machines scan the blood and the software automatically recognizes and classifies the cells in fractions of a second using artificial intelligence.
2. the moat (The monopoly)
The company does not operate in just any competitive market, but has a global market share of over 80% in the niche of automated digital cell morphology. 80 %. If you want to work efficiently as a central laboratory today, you simply cannot ignore CellaVision.
3. the bare facts & key figures (as at the end of March 2026)
- WKN / ISIN: 508218 / SE0000683484
- Current share price: ~ SEK 150.00 (approx. EUR 13.00)
- Market capitalization: ~ SEK 3.5 billion
- P/E ratio (price/earnings ratio): ~ 23.5 (A massive discount to the historical average!)
- Dividend yield: ~ 1.83% (Raised to SEK 2.75 for the year just ended)
- Balance sheet: Equity ratio of > 80%, virtually debt free.
4. why has the share crashed? (The reality check)
If a company is so brilliant, why is the share price so low? The market mercilessly pulled the plug at the end of 2025 and beginning of 2026. The reason: growth in the important Asian market (especially China) slumped massively in Q4, and negative currency effects put additional pressure on the balance sheet. Wall Street hates surprises in growth stocks - and has slashed the P/E ratio from over 40 to under 24.
5. chart analysis of the last few months
This is a classic "fallen knife" that is currently looking for a bottom. It went from over SEK 200 down to a 52-week low of SEK 139.20. The good news is that the sell-off appears to have stopped. The share is currently stabilizing at around SEK 150 and forms a solid fundamental basis. Anyone buying here is buying in the absolute valley of tears. $CEVI (-2,11%)
6. the formula check (quality & cash flow)
We rigorously filter such stocks according to hard figures:
- Sales Growth + Operating Margin = Score: Organic growth in 2025 was around 9% despite the Asian crisis (driven by massive +50% growth in the Americas). The operating EBIT margin remains at an outstanding 26%.
- Result: 9 + 26 = Score 35! (> 25 = very good). The company continues to print money reliably. The dividend is fully covered by the free cash flow. Our quality filter is passed with flying colors.
7. future prospects & catalysts
The large central laboratories are supplied. The new growth market is small and medium-sized laboratories. CellaVision has launched the compact "DC-1" system precisely for this purpose. Another massive catalyst will be the new bone marrow application, which is being launched in Europe and will open up completely new market segments.
8. competition & market environment
There is hardly any real direct competition at this high-end level. Large medical technology giants such as the Japanese company Sysmex do not try to copy CellaVision, but use the Swedes as their exclusive partner and integrate their systems directly into their own gigantic blood analysis lines.
9 Special Entry Zones (The "Bargain Hunter's List")
If you want to play the turnaround, use the following zones:
- Zone 1 (The current bottom): ~ SEK 146 to 150. This is the current consolidation level. A historically favorable entry point for this world market leader.
- Zone 2 (The crisis low): ~ SEK 139. The absolute 52-week low. If the share price falls through here on a sustained basis, the short-term turnaround story has failed for the time being.
10. profit margins & scalability
Why is CellaVision so incredibly profitable? Although they sell hardware (the microscopes), they operate in the background like a pure software company. The gross margin is almost 69%! As soon as the device is in the hospital, revenue flows continuously through high-margin software licenses, new analysis applications and service contracts.
11. the voices from the engine room (CEO & Management)
CEO Simon Østergaard makes no secret of the current dip in business in Asia, but is ice-cold in his focus on strategic expansion. He emphasizes the enormous growth on the American continent and is extremely bullish about the future: "We are confident that we are sitting on a disruptive microscopy solution here." The management sees the global addressee market growing from SEK 2 billion to over SEK 5 billion in the coming years. Fun fact: The insiders (including founders) used the share price slide at the beginning of the year to privately buy massive amounts of their own shares!
12. analysts' opinions (consensus & price targets)
The financial professionals see the current crash as exaggerated. The analysts' consensus (e.g. from Pareto Securities) is adamantly "buy" ("Strong Buy"). The average 12-month price target is a massive 228 to 230 SEK! From the current level of ~150 SEK, this means a calculated upside potential of over 50 %. Above all, analysts praise the flawless, debt-free balance sheet and the gigantic cash generation, which extremely limits the downside risk at this price level.
Closing & Conclusion: CellaVision $CEVI (-2,11%) is currently not a classic momentum play, but a hard value turnaround investment. You are buying an absolute medical monopoly that delivers an EBIT margin of 26% at a price that has not been this attractive for a long time. The P/E ratio has been halved, insiders are buying and analysts see 50% upside potential. Anyone with the patience to sit out the current sideways movement until the Asian dip has been ironed out could see an extremely profitable hidden champion grow in their portfolio in the long term.
How do you see it? Do you buy into such "fallen monopolies" at the bottom, or do you only buy stocks that are already in a clear upward trend towards all-time highs?
@Liebesspieler
@Tenbagger2024
@Multibagger
@Dividendenopi
@schlimmschlimm
@Get_Rich_or_Die_Tryin
@Klein-Anleger
@TradingHase
@Simpson
@NichtRelevant
@Abyss
@SAUgut777
@HoldTheMike and everyone else :)
